This mechanism helps with weight loss, but eating certain foods can trigger nausea, vomiting, or digestive discomfort
In January 2026, a pill version of Wegovy (semaglutide) became available in the U.S after receiving FDA approval in December 2025
Overweight and obesity, in particular, intra-abdominal adiposity, are associated with various cardiometabolic conditions including type 2 diabetes (T2D), dyslipidemia, hypertension, atherosclerotic cardiovascular disease, and heart failure [2, 3]
Dispose of used needles in a proper sharps container
Glucagon receptor activation increases energy expenditure, promotes hepatic fat oxidation, and drives lipolysis
These warnings are particularly relevant in the context of injectable GLP-1 and related receptor agonists, a class that has seen a significant rise in falsified and substandard products circulating in the UK